|
Casey Crawford Lynch, Managing Director
As founder and Managing Director of NeuroInsights, Casey works with companies to develop and implement strategic business plans and helps investors identify and profit from opportunities in neurotechnology. She is co-author of The Neurotechnology Industry Report, a comprehensive market analysis and strategic investment report on the brain industry and is the Managing Editor of Neurotech Insights, the neurotechnology investment newsletter. Casey is also on the Board of Directors of The Neurotechnology Industry Organization, a trade association for commercial neuroscience, and the co-founder and president of The Neurotechnology Development Foundation, a new non-profit formed to support translational research.
Previously, Casey was the co-founder and CEO of Aspira Biosystems, a venture backed drug discovery platform-company, which was acquired by Nanomune Inc. in 2004. Prior to the four years building Aspira, Casey oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals. There, she established disease model testing paradigms for multiple sclerosis, uveitis, and other neurological disorders.
Casey conducted primate preclinical trials for Alzheimer’s disease treatment at the Wadsworth Medical Center in Los Angeles and researched the neurological basis of schizophrenia and epilepsy at UCLA. Her graduate work on neurotrophic factor cell biology and neurodegenerative diseases was carried out in the Mobley lab at UCSF/ Stanford University and was funded by the NSF and an Alzheimer's Association Zenith Award. In addition to a BS in neuroscience from UCLA, she has an MS in neuroscience from UCSF and has completed the Management Development for Entrepreneurs (MDE) program of the Anderson School of Business.
|
Frank Eeckman MD, PhD
Dr. Frank Eeckman is an analyst and consultant at NeuroInsights helping companies and investors identify and vet opportunities in neurotechnology. He writes indication and company features for Neurotech Insights, the neurotechnology industry newsletter published by NeuroInsights. He is the Director of Regulatory Policy at The Neurotechnology Industry Organization and co-founder and Chief Science Officer of Centient Biotech. Dr. Eeckman was an early innovator in the genomics revolution, leading Lawrence Berkeley National Laboratories’ bioinformatics team on the Human Genome Project. He has helped launch three biotech startups and headed discovery groups at Parke-Davis and Pfizer. He serves on the Scientific Advisory Board of several biotech companies, and provides investment analysis to venture capitalists and fund managers as well as consulting to both large and small companies.
Dr. Eeckman holds an MD cum laude from the University of Ghent Medical School, Belgium, where he was trained as a neurologist. He also earned a PhD in Neurophysiology at the University of California Berkeley, where he was a Fulbright Scholar.
|
|
